Programm                 "Degeneration und Regeneration– Grundlagen, Diagnostik und Therapie"


Hotelbuchung
   Hotel Registration
Grußwort
   Welcome address
Beteiligte Gesellschaften
   Societies involved
DOG Information
   DOG Information
Eröffnung des Kongresses
   Opening Ceremony
Preise
   Awards
Ablauf der Tagung 2003
   General overview of congress
Lageplan der Räumlichkeiten
   Map of Congress Center
Wissenschaftliche Themen
   Scientific topics
Symposien
   Symposia
Wissenschaftliches Programm
   Scientific program
Posterpräsentationen
   Poster Presentation
Kurse
   Courses
Begleitende Veranstaltungen
   Accompanying program
Arbeitssitzungen
   Working sessions
Rahmenprogramm
   Social program
Allgemeine Informationen
   General Information
Autorenindex
   Index of Authors
Industrieaussteller
   Commercial exhibitors
Sponsoren
   Sponsors
Impressum



DOG Homepage


Abstract
Abstract

FTY720 Prolongs Clear Corneal Allograft Survival with a Differential Effect on Different Lymphocyte Populations

Mayer K.1, Birnbaum F.1, Reinhard T.1, Reis A.1, Braunstein S.3, Claas F.4, Sundmacher R.1
1Eye Hospital, 3Departement of Pathology, Heinrich-Heine University, Duesseldorf; 2Eye Hospital, Albert-Ludwigs-University, Freiburg; 4Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands

Purpose: FTY720 is a potent immunomodulator with unique effects on lymphocyte homing and has recently proven to be safe and effective in renal transplantation in man. We investigated the potency of FTY720 in inhibiting allograft rejection in the rat keratoplasty model.
Method: Penetrating keratoplasties were performed using Fisher rats as donors and Lewis rats as recipients or donors: group 1 (n= 10): allogeneic control; group 2 (n= 10): Lewis/Lewis syngeneic control; group 3 (n= 9): mycophenolate mofetile 40 mg/kg; group 4 (n= 10): FTY720 1.2 mg/kg; group 5 (n= 8): FTY720 0.3 mg/kg. Four animals of each group were sacrificed for immunohistological evaluation on day 14. Medication in the therapy groups was given for the duration of 18 days.
Results: The mean rejection free graft survival time was 11.3 (±0.8) days for the allogeneic control (group 1), 24.6 (± 2.5) days for group 3 (MMF 40 mg/kg), 44.5 (± 5.7) days for group 4 (FTY720 1.2mg/kg) and 35.3 (± 5.7) days for group 5 (FTY720 0.3 mg/kg) (p<


Zurück | Back